KRYS

ROSSI DINO A

Known title: DirectorCIK: 0001209059

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 6, 2026

Krystal Biotech: Analysts Question Durability of Rare-Disease Drug Moat. Recent analysis focuses on whether Krystal Biotech's rare-disease drug has a durable competitive advantage. This question is relevant as the stock trades near its 52-week high, with a trailing P/E of 39.5. The current price action shows a support rejection, indicating potential short-term volatility.

this person other insiders at KRYS

Transaction History

KRYS▼ Sell$0
KRYS▼ Sell$111K
KRYS▼ Sell$747K
KRYS▼ Sell$1.7M
KRYS▼ Sell$554K
KRYS▼ Sell$2.4M
KRYS▼ Sell$1.6M
KRYS▼ Sell$1.0M
KRYS▼ Sell$13K
KRYS▲ Buy$167K
KRYS▼ Sell$2.1M
KRYS▼ Sell$2.8M
KRYS▼ Sell$0
KRYS▼ Sell$3.3M

We use analytics to understand how market-wall is used. No personal data is sold.